MAA
RPRX icon

Mraz Amerine & Associates’s Royalty Pharma RPRX Stock Holding History

Mraz Amerine & Associates’s Portfolio RPRX Stock Details RPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$255K Hold
4,550
– – 0.04% 156
2026
Q1 		$218K Buy
+4,550
New +$199K 0.03% 165

Other funds holding RPRX

Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Swedbank
Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Mraz Amerine & Associates's RPRX Position: Q2 2026 in Review

Mraz Amerine & Associates held its Royalty Pharma (RPRX) position steady in Q2 2026 at 4,550 shares worth $255K. The position accounts for 0.04% of the portfolio, ranked #156.

Mraz Amerine & Associates first reported a position in RPRX in Q1 2026 and has held it in 2 quarters since. 643 funds tracked by Wall St. Rank hold RPRX as of Q2 2026.

  • Mraz Amerine & Associates held 4,550 shares of Royalty Pharma worth $255K as of Q2 2026.
  • Mraz Amerine & Associates left its Royalty Pharma share count unchanged in Q2 2026.
  • Royalty Pharma made up 0.04% of Mraz Amerine & Associates's portfolio in Q2 2026, its #156 holding.
  • Mraz Amerine & Associates first reported a position in Royalty Pharma in Q1 2026 and has held it in 2 quarters since.
  • 643 funds tracked by Wall St. Rank held Royalty Pharma as of Q2 2026.

Based on Mraz Amerine & Associates's 13F filing for Q2 2026, filed 16 Jul 2026.